Valuation: ISIS Pharmaceuticals, Inc.

Market Cap 860.34Cr 747.89Cr 696.12Cr 639.13Cr 1.21TCr 82TCr 1.23TCr 8.21TCr 3.22TCr 41TCr 3.23TCr 3.16TCr 1,37100Cr P/E 2026 *
-14.6x
P/E 2027 * -28.3x
Enterprise Value 820.78Cr 713.5Cr 664.12Cr 609.74Cr 1.15TCr 78TCr 1.17TCr 7.83TCr 3.07TCr 39TCr 3.08TCr 3.01TCr 1,30800Cr EV / Sales 2026 *
8.9x
EV / Sales 2027 * 5.97x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.33%+2.73% - - 860.34Cr
-1.40%+2.59%-1.71%+11.28% 4.85TCr
-2.41%-0.90%+411.96%+495.33% 3.99TCr
-1.16%+12.96%+28.81%+7.25% 3.87TCr
-1.88%-3.03%+5.69%+53.00% 3.51TCr
-1.74%+5.12%+14.44%+41.77% 2.98TCr
-0.21%-4.04%+36.40%+125.75% 1.61TCr
-2.85%-3.92% - - 1.61TCr
-0.64%+2.65%+3.40%+13.11% 1.36TCr
-1.19%-1.32%-1.73%-34.37% 1.26TCr
Average -1.22%+1.05%+62.16%+89.14% 2.78TCr
Weighted average by Cap. -1.50%+2.03%+79.78%+108.61%

Financials

2026 *2027 *
Net sales 92Cr 80Cr 75Cr 69Cr 129.38Cr 8.8TCr 131.39Cr 879.62Cr 345.23Cr 4.38TCr 346.37Cr 338.76Cr 15TCr 140.16Cr 121.84Cr 113.41Cr 104.12Cr 196.62Cr 13TCr 199.67Cr 1.34TCr 524.64Cr 6.66TCr 526.38Cr 514.82Cr 22TCr
Net income -59Cr -51Cr -48Cr -44Cr -83Cr -5.63TCr -84Cr -562.14Cr -220.62Cr -2.8TCr -221.36Cr -216.49Cr -9.39TCr -32Cr -28Cr -26Cr -24Cr -44Cr -3.02TCr -45Cr -302Cr -118.53Cr -1.5TCr -118.92Cr -116.31Cr -5.05TCr
Net Debt -40Cr -34Cr -32Cr -29Cr -55Cr -3.78TCr -56Cr -377.26Cr -148.06Cr -1.88TCr -148.55Cr -145.29Cr -6.3TCr -24Cr -21Cr -19Cr -18Cr -34Cr -2.3TCr -34Cr -229.54Cr -90Cr -1.14TCr -90Cr -88Cr -3.84TCr
Logo ISIS Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-